 |
|
Volume 3, Number 1 |
|
| Lung cancer diagnosis: time for a new approach? |
Trevor K Rogers MD FRCP Consultant Chest Physician, Chest Clinic, Doncaster Royal Infirmary |
The explanation for the relatively low rates of survival (5–6% at five years) and of radical therapy for British lung cancer patients, compared to those in other developed health economies (8–15% five-year survival), is unclear. |
|
| Oral versus intravenous drugs for lung cancer |
Jason F Lester MBBS MRCP FRCR Consultant Clinical Oncologist, Velindre Hospital, Cardiff |
Nearly 35,000 cases of lung cancer are diagnosed in England and Wales every year and around 80% of these are non-small cell lung cancer (NSCLC). Only 15–20% of newly diagnosed patients with NSCLC are suitable for potentially curative treatment, and the majority of these will relapse either locally or systemically. |
|
| The impact of emergency hospital admissions for lung cancer in the UK |
Colin Selby DM FRCPEDM FRCPE Consultant in Respiratory and Intensive Care Medicine, Queen Margaret Hospital, Fife |
Lung cancer is the most common solid cancer in both males and females in the UK. Despite substantial improvements in the diagnosis and management of these patients in the last decade, it still has a bleak outlook for the majority. In the UK, barely 25% of these patients are alive 12 months after their diagnosis. |
|
| How practice-based commissioning will affect patients |
Orest Mulka BA MBBS FRCGP GP, Measham and Macmillan GP Facilitator, Cancer Lead, Charnwood and North West Leicestershire Primary Care Trust |
GPs are currently waking up to the exciting possibilities of practice-based commissioning (PBC). The main aim of PBC is to encourage GPs to commission or perform more services, either in the surgery or closer to the patient’s home (as opposed to getting them seen in hospital). |
|
| The management of lung cancer in primary care |
Michael D Peake, Editor |
The role of the diagnosis and management of lung cancer patients in the community is important. Primary care is changing rapidly and there are both opportunities and risks associated with these changes. |
|
| Secondline chemotherapy in NSCLC |
Leila Khoja MbChB MRCP Specialist Registrar; Mohammed Mulyati MBBS MRCP Clinical Fellow Siow Ming Lee PhD FRCP Consultant Medical Oncologist, Whittington and University College Hospitals, London |
Approximately 37,000 new cases of lung cancer are diagnosed each year in the UK. An estimated 33,000 individuals die from the disease and non-small cell lung cancer (NSCLC) makes up about 80% of the cases. |
|
